Dutch biotech Laigo Bio has launched with 11.5 million euros ($12.7 million) in seed financing to progress its SureTAC ...

Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and oncology UTRECHT, the Netherlands - 4 December 2025 (08:30 CET). Laigo ...

Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line therapy for uHCCThe ...

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has provided an announcement. Shanghai Henlius Biotech, Inc. announced that its ...

AstraZeneca AZN and Merck MRK are both major global pharmaceutical companies with diversified drug portfolios. While Merck is ...

TiumBio lists Tosposertib as WHO international nonproprietary name and advances phase 2 trials in Korea TiumBio advances ...

Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...

Intended to Maximize Stakeholder Value Through Structured Process -- Validated SCS Microinjector® Delivery Platform Anchored by Commercial ...

Background Hereditary haemorrhagic telangiectasia (HHT) and juvenile polyposis syndrome (JPS) can be caused by SMAD4 pathogenic variants. SMAD4 is a common transcription factor of the BMP/TGFβ ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

This important study describes a deep learning framework that analyzes single-cell RNA data to identify a tumor-agnostic gene signature associated with brain metastases. The identified signature ...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory ...